AVEO Pharmaceuticals — Investor Presentation (September 2019)
31 slides from AVEO Pharmaceuticals's investor presentation, Sep 10, 2019
Slide 1: AVEO Overview September 2019
AVEO Overview September 2019 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: AVEO Oncology: Strategy for Value Creation
AVEO Oncology: Strategy for Value Creation Value Enhancing Partnerships Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA™ (tivozanib) – IO Combinations (RCC, HCC, other) Highly specific VEGFR TKI has potential to enable unique tolerab
Slide 4: Pipeline: Multiple Potential Opportunities for Value Creation
Clinical Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib (RCC) VEGFR 123 TKI Tivozanib (HCC) VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb Multiple Potential Opportunities for Value Creation TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (P
Slide 5: Financial Highlights
Financial Highlights Cash on hand to fund planned operations into 3Q 2021* $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 $25.0M upfront payment from Kyowa Kirin due in 3Q 2019 Kyowa Kirin buy back of tivozanib non-oncology rights: $25M upfront payment Waiver of the $18M p
Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase 3 Study
FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71
Slide 8: TIVO-3: Study Design
TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4
Slide 9: Primary Endpoint: Progression-Free Survival per IRC (ITT)
Primary Endpoint: Progression-Free Survival per IRC (ITT)* Median PFS, mo (95% CI) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7, 5.6) HR, 0.73 (95% CI: 0.56, 0.94) P=0.0165 2yr PFS 18% 5% 28% 1yr PFS 11% 44% improvement in median PFS 27% risk reduction for progression or death *Final analysis, as of
Slide 10: IO Subgroup Progression-Free Survival per IRC
IO Subgroup Progression-Free Survival per IRC (26% of ITT)* Median PFS, mo (95% CI) Tivozanib 7.3 (5.3, 11.1) Sorafenib 5.1 (3.6, 7.4) HR, 0.55 (95% CI: 0.32, 0.94) P=0.028 35% 1yr PFS 4% 2yr PFS 25% 43% improvement in median PFS 45% risk reduction for progression or death *Final analysis, as of Oct
Slide 11: Secondary Endpoint – ORR
Secondary Endpoint – ORR* Final Analysis - Superior Overall Response Rate and Durability Statistically significant benefit in ORR, p=0.02 Durable responses with tivozanib: 55% remaining in response past 2 years Median DoR: tivozanib not reached vs sorafenib 5.7 months *Final analysis, as of Oct 4, 2
Slide 12: Treatment-Related Adverse Events
Treatment-Related Adverse Events* (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphon
Slide 13: Tolerability Results
Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions (%) 24 38 AEs Leading to Dose Interruption (%) 48 63 Treatment Related SAEs (%) 11 10 Treatment Related Deaths (%) 0 0 Deaths within 30 days of Tx (N) 15 12 Exposure Adj Deaths per Month of
Slide 14: Secondary Endpoint – Overall Survival
Secondary Endpoint – Overall Survival Initial OS Analysis (Oct 4, 2018): HR* >1.00 Analysis based on 183 OS events Prespecified OS Analysis update (Aug 15, 2019): HR*=0.99 Analysis based on 227 OS events 95% CI: 0.76-1.29; p=0.95 44 additional events since Oct 4, 2018 data cut 16 tivozanib events an
Slide 15: TIVO-3 Conclusions
TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni
Slide 16: PD-1 Combination Opportunities
PD-1 Combination Opportunities
Slide 17: Tivozanib Properties May Provide Advantages in Combination with IO Therapy
Tivozanib Properties May Provide Advantages in Combination with IO Therapy Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017
Slide 18: Demonstrated Favorable Safety Results
Demonstrated Favorable Safety Results 60% of patients experienced treatment related grade 3/4 adverse event Excluding uncomplicated hypertension, only 44% of patients experienced grade 3/4 adverse event Minimal off-target AEs observed, likely due to high specificity of tivozanib Barthelemy et al. ES
Slide 19: Encouraging Preliminary Efficacy Results
Encouraging Preliminary Efficacy Results 56% ORR and 96% DCR 72% had tumor shrinkage ≥25% as of August 2018 4% (1/25) of patients had a complete response 52% (13/25) of pts remain on therapy Results suggest additive or synergistic efficacy for tivozanib + PD1 Barthelemy et al. ESMO 2018 Updated Resu
Slide 20: Immuno-Oncology Clinical Collaboration with AstraZeneca
Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Single agent activity demonstrated for tivozanib and durvalumab in HCC2,3. Combination of two agents has potential to show enhanced efficacy and best in class tolerability profile among TKI/IO regimens. Planned phase 1/2 stu
Slide 21: Tivozanib Commercial Opportunity
Tivozanib Commercial Opportunity
Slide 22: Significant Potential Commercial Opportunity for Tivozanib in the United States
If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market (est. 2020) ~$1.6B1 2nd Line Market (est. 2020) ~$700M1 3rd Line+ Market (est. 2020) ~$300M1 Expect opportunity to expand Potential to be first agent indicated for 3rd & 4th line Only pivotal
Slide 23: Potential Relevance of Tivozanib in Refractory RCC
Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party US Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using d
Slide 24: FOTIVDA Commercialization in EU and ROW
First-line treatment for patients with good or intermediate risk Second-line patients following TKIs Launched in Germany, Spain and UK Approved in New Zealand https://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma FOTIVDA Commercialization in EU and ROW This Photo by Unknown Auth
Slide 25: Pipeline and Near-Term Milestones
Pipeline and Near-Term Milestones
Slide 26: Tivozanib
Tivozanib * Does not include potential PTE up to 5 yr max VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC IO combination study with OPDIVO® in collaboration with BMS unde
Slide 27: Ficlatuzumab
Ficlatuzumab * Does not include potential PTE up to 5 yr max HGF Inhibitory Antibody with Optimal Blockade of c-Met AML: Phase 1/2 Trial of ficlatuzumab and cytarabine in refractory AML patients Demonstrated 50% complete response in patients refractory to initial therapy Randomized phase 2 in planni
Slide 28: Anti-ERBB3 Mab with Broad Therapeutic Potential
Anti-ERBB3 Mab with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40M development and regulatory/$90M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squamous cell esophageal cancer (IND
Slide 29: First-in-Class, Anti-GDF15 MAb for Cachexia
First-in-Class, Anti-GDF15 MAb for Cachexia Affects approximately 5 million patients in the US alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths1,2 Pre-clinical development underway to enable planned IND submission in 2020 Composition
Slide 30: AVEO Key Near Term Potential Milestones
AVEO Key Near Term Potential Milestones Tivozanib (VEGFR 1, 2 and 3 TKI) 2H19 1H20 2H20 TIVO-3 OS Update / Regulatory Discussion DEDUCTIVE HCC Ph 1/2 (Durvalumab + Tivo) Enrollment Start TiNivo RCC (Nivolumab + Tivo) Final PFS Presentation Ficlatuzumab (HGF Inhibitory Antibody) 2H19 1H20 2H20 AML Ra
Slide 31: AVEO Overview September 2019
AVEO Overview September 2019
AVEO Pharmaceuticals — Investor Presentation (September 2019) on 6ix